Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-t5pn6 Total loading time: 0 Render date: 2024-04-20T02:57:45.620Z Has data issue: false hasContentIssue false

37 - Management of melanoma

Published online by Cambridge University Press:  05 November 2015

By
Satish Kumar  and
Julie Martin
Edited by
Louise Hanna ,
Tom Crosby  and
Fergus Macbeth
Satish Kumar
Affiliation:
Velindre Cancer Centre, Velindre Hospital, Cardiff, UK
Julie Martin
Affiliation:
Royal Glamorgan Hospital, Mid Glamorgan, UK
Louise Hanna
Affiliation:
Velindre Cancer Centre, Velindre Hospital, Cardiff
Tom Crosby
Affiliation:
Velindre Cancer Centre, Velindre Hospital, Cardiff
Fergus Macbeth
Affiliation:
Velindre Cancer Centre, Velindre Hospital, Cardiff
Get access

Summary

Introduction

Melanocytes originate in the neural crest of the embryo and migrate widely during development to locations such as the basal layer of the epidermis and the uveal tract. As a result, malignant melanoma (MM) can affect sites other than the skin, including the central nervous system (e.g. meninges and uveal tract) and the aerodigestive and genitourinary tracts (e.g. nasopharynx, oral cavity and vagina). Cutaneous melanoma has one of the fastest rising cancer incidences worldwide. In the UK it is the fifth commonest cancer and the second commonest cancer in the 15–34 year age group, with about 27% of cases occurring below the age of 50 (http://www.cancerresearchuk.org/, accessed February 2015).

Mortality rates have also increased over time, but less so than the increase in incidence because of improvements in the chance of survival from melanoma. Mortality rates appear to have stabilised in some countries, most notably Australia. A shift to proportionately more in situ and thin melanomas being diagnosed in the same period suggests that this reduction in mortality may be due to earlier detection (Coory et al., 2006).

This chapter focuses on cutaneous melanoma, but will also cover some of the main features of the rarer subtypes such as mucosal and ocular melanoma.

Cutaneous melanoma

Types of cutaneous melanoma

The main clinicopathological varieties of cutaneous MM are superficial spreading, nodular, acral lentiginous and lentigo maligna melanoma.

Incidence and epidemiology

The annual age-standardised disease incidence of cutaneous melanoma in the UK is 17 per 100,000. Approximately 11,500 new cases are diagnosed per year in England and Wales, comprising 4% of all new cancer cases. Around 2000 deaths from melanoma occur annually in the UK (from Cancer Research UK, http://www.cancerresearchuk.org/, accessed February 2014).

The incidence of cutaneous melanoma has continued to rise worldwide for the last 40 years. The annual increase varies between populations, but in general has been in the order of 3–7% per year for fair-skinned Caucasian people. Some of this increase may be due to increased surveillance and therefore earlier detection, as well as changes in diagnostic criteria. However, most of the increase is considered real, and linked to changes in lifestyle resulting in excessive recreational exposure to sunlight (Lens and Dawes, 2004).

Type
Chapter
Information
Practical Clinical Oncology , pp. 499 - 512
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Balch, C. M., Soong, S. J., Bartolucci, A. A., et al. (1996). Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann. Surg., 224, 255–266.CrossRefGoogle ScholarPubMed
Balch, C. M., Soong, S., Ross, M. I., et al. (2000). Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Ann. Surg. Oncol., 7, 87–97.CrossRefGoogle Scholar
Balch, C. M., Atkins, M. B. and Sober, A. J. (2004). Cutaneous melanoma. In Cancer: Principles and Practice of Oncology, Ed. Devita, V. T., Jr., Hellman, S. and Rosenberg, S. A., 7th edn. Philadelphia, PA: JB Lippincott, pp. 1754–1808.Google Scholar
Balch, C. M., Gershenwald, J. E., Soong, S., et al. (2009). Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol., 27, 6199–6206.CrossRefGoogle ScholarPubMed
Ben-Porat, L., Panageas, K. S., Hanlon, C., et al. (2006). Estimates of stage-specific survival are altered by changes in the 2002 American Joint Committee on Cancer staging system for melanoma. Cancer, 106, 163–171.CrossRefGoogle ScholarPubMed
Boland, G. M. and Gershenwald, J. E. (2012). Sentinel lymph node biospy in melanoma. Cancer J., 18, 185–191.CrossRefGoogle Scholar
Boniol, M., Autier, P., Boyle, P, et al. (2012). Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis. Br. Med. J., 345, e4757.CrossRefGoogle ScholarPubMed
Breslow, A. (1970). Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann. Surg., 172, 902–908.CrossRefGoogle ScholarPubMed
Burmeister, B. H., Henderson, M. A., Ainslie, J., et al. (2012). Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol., 13, 589–597.CrossRefGoogle ScholarPubMed
Chapman, P. B., Einhorn, L. H., Meyers, M. L., et al. (1999). Phase III multicenter randomised trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J. Clin. Oncol., 17, 2745–2751.CrossRefGoogle Scholar
Clark, W. H. Jr., From, L., Bernardino, E. A., et al. (1969). The histogenesis and biologic behaviour of primary human malignant melanomas of the skin. Cancer Res., 29, 705–726.Google Scholar
Coory, M., Baade,. P, Aitken, J., et al. (2006). Trends for in-situ and invasive melanoma in Queensland, Australia, 1982–2002. Cancer Causes Control, 17, 21–27.CrossRefGoogle Scholar
Damato, B., Kacperek, A., Chopra, M., et al. (2005). Proton beam radiotherapy of choroidal melanoma: the Liverpool-Clatterbridge experience. Int. J. Radiat. Oncol. Biol. Phys., 62, 1405–1411.CrossRefGoogle ScholarPubMed
Diener-West, M., Earle, J. D., Fine, S. L., et al. (2001). The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch. Ophthalmol., 119, 969–982.Google ScholarPubMed
Eggermont, A. M., Suciu, S., Testori, A., et al. (2012). Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J. Clin. Oncol., 30, 3810–3818.CrossRefGoogle ScholarPubMed
Eggermont, A. M., Chiarion-Sileni, V., Grob, J. J., et al. (2014). Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial. J. Clin. Oncol., 32(5), Suppl.; abstr. LBA9008.CrossRefGoogle Scholar
Fitzpatrick, T. B., Rhodes, A. R., Sober, A. J., et al. (1988). Primary malignant melanoma of the skin: the call for action to identify persons at risk; to discover precursor lesions; to detect early melanomas. Pigment Cell, 9, 110–117.Google Scholar
Fuss, M., Loredo, L. N., Blacharski, P. A., et al. (2001). Proton radiation therapy for medium and large choroidal melanoma: preservation of the eye and its functionality. Int. J. Radiat. Oncol. Biol. Phys., 49, 1053–1059.CrossRefGoogle ScholarPubMed
Hanson, P. W., Elaimy, A. L., Lamoreaux, W. T., et al. (2012). A concise review of the efficacy of stereotactic radiosurgery in the management of melanoma and renal cell carcinoma brain metastases. World J. Surg. Oncol., 10, 176.CrossRefGoogle ScholarPubMed
Hauschild, A., Grob, J. J., Demidov, L. V., et al. (2012). Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label,phase 3 randomised controlled trial. Lancet, 380, 358–365.CrossRefGoogle ScholarPubMed
Hodi, F. S., O'Day, S. J., McDermott, D. F., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med., 363, 711–723.CrossRefGoogle ScholarPubMed
Larkin, J., Ascierto, P. A., Dréno, B., et al. (2014). Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med., 371, 1867–1876.CrossRefGoogle ScholarPubMed
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. (2015). Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med., 373, 23–34.CrossRef
Lens, M. B. and Dawes, M. (2004). Global perspectives of contemporary epidemiogical trends of cutaneous malignant melanoma. Br. J. Dermatol., 150, 179–185.CrossRefGoogle Scholar
Long, G. V., Stroyakovskiy, D., Gogas, H., et al. (2014). Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N. Engl. J. Med., 371, 1877–1888.CrossRefGoogle ScholarPubMed
MacKie, R. M. (1989). Malignant Melanoma: A Guide to Early Diagnosis. Glasgow: University of Glasgow.Google Scholar
Mali, B., Jarm, T., Snog, M., et al. (2013). Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis. Eur. J. Surg. Oncol., 39, 4–16.CrossRefGoogle ScholarPubMed
Marsden, J. R., Newton-Bishop, J. A., Burrows, L., et al. (2010). Revised U.K. Guidelines for the management of cutaneous melanoma 2010. Br. J. Dermatol., 163, 238–256.CrossRefGoogle ScholarPubMed
McArthur, G. A., Chapman, P. B., Robert, C., et al. (2014). Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol., 3, 323–332.Google Scholar
Mocellin, S., Lens, M. B., Pasquali, S., et al. (2013). Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst Rev., 6, CD008955.Google Scholar
Morton, D. L., Cochran, A. J., Thompson, J. F., et al. (2005). Sentinel node biopsy for early stage melanoma – accuracy and morbidity in MSLT-1, an international multi-centre trial. Ann. Surg., 242, 302–313.Google Scholar
Morton, D. L., Thompson, J. F., Cochran, A. J., et al. (2006). Sentinel-node biopsy or nodal observation in melanoma.N. Engl. J. Med., 355, 1307–1317.CrossRefGoogle ScholarPubMed
Morton, D. L., Thompson, J. F., Cochran, A. J., et al. (2014). Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N. Engl. J. Med., 370, 599–609.CrossRefGoogle ScholarPubMed
Newton-Bishop, J. A., Beswick, S., Randerson-Moor, J., et al. (2009). Serum 25-hydroxyvitamin D3 levels are associated with Breslow thickness at presentation and survival from melanoma.J. Clin. Oncol., 27, 5439–5444.CrossRefGoogle ScholarPubMed
NICE. (2012a). Ipilumumab for Previously Treated Advanced (Unresectable or Metastatic) Melanoma. Technology Appraisal Guidance [TA268].London: National Institute for Health and Care Excellence.
NICE. (2012b). Vemurafenib for Treating Locally Advanced or Metastatic BRAF V600 Mutation-Positive Malignant Melanoma. Technology Appraisal Guidance [TA269].London: National Institute for Health and Care Excellence.
NICE. (2014a). Ipilumumab for Previously Treated Advanced (Unresectable or Metastatic) Melanoma. Technology Appraisal Guidance [TA319].London: National Institute for Health and Care Excellence.
NICE. (2014b). Dabrafenib for Treating Unresectable or Metastatic BRAF V600 Mutation-Positive Melanoma. Technology Appraisal Guidance [TA321].London: National Institute for Health and Care Excellence.
Ribas, A., Puzanov, I., Dummer, R., et al. (2015). Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma. (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol., 16, 908–918.CrossRef
Robert, C., Karaszewska, B., Schachter, J., et al. (2015). Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med., 372, 30–39.CrossRefGoogle ScholarPubMed
Robert, C., Long, G. V., Brady, B., et al. (2015). Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320–330.CrossRef
Roberts, D. L., Anstey, A. V., Barlow, R. J., et al. (2002). U.K. guidelines for the management of cutaneous melanoma. Br. J. Dermatol., 146, 7–17.CrossRefGoogle ScholarPubMed
Roberts, D. and Crosby, T. (2003). Cutaneous melanoma. In BMJ Books. Evidenced Based Dermatology, ed. Williams, H., Bigby, M., Diegpen, T.et al.Oxford: Blackwell Publishing, Chapter 24.Google Scholar
Ross, M. I (2010). Sentinel node biospy for melanoma: an update after two decades of experience. Semin. Cut. Med. Surg., 29, 238–248.CrossRefGoogle Scholar
Schadendorf, D., Hodi, F. S., Robert, C., et al. (2013). Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. Eur. J. Cancer, 49, Suppl. 3, abstr. LBA 24.Google Scholar
Sim, F. H., Taylor, W. F., Pritchard, D. J., et al. (1986). Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin. Proc., 61, 697–705.CrossRefGoogle Scholar
Steel, G. G. (2002). Basic Clinical Radiobiology, 3rd edn. London: Arnold.Google Scholar
Thomas, J. M. (2008). Sentinel lymph node biopsy in malignant melanoma. Br. Med. J., 336, 902–903.CrossRefGoogle ScholarPubMed
Veronesi, U., Adamus, J., Bandiera, D. C., et al. (1982). Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer, 49, 2420–2430.3.0.CO;2-2>CrossRefGoogle Scholar
Weber, J. S., D'Angelo, S. P., Minor, D., et al. (2015). Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol., 16, 375–384.CrossRef
Wolchok, J. D., Hoos, A., O'Day, S., et al. (2009). Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res., 15, 7412–7420.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×